This week, Genomeweb has an excellent article about reimbursement and policy changes in German regarding NGS. The article includes a number of important commentaries from experts.
As an AI experiment, I was curious how well Chat GPT could read the underlying 8-page and 35-page dense government documents in German, and turn them into an article for English-speaking US readers. While I can read German, I have not checked the 43 pages of original documents against the Chat GPT output.
###
BERLIN — Germany’s national physician-fee-setting process has approved a major restructuring of outpatient reimbursement for human genetic in-vitro diagnostics, updating a 2016-era payment framework for next-generation sequencing while adding explicit price cuts, volume degressions, and tighter billing architecture for high-growth genetic testing.
The June 9 decision by the Erweiterter Bewertungsausschuss — the Extended Evaluation Committee that sets the Einheitlicher Bewertungsmaßstab, or EBM, for physicians treating patients in Germany’s statutory health insurance system — takes effect Oct. 1, 2026. For U.S. readers, the EBM is roughly analogous to a national physician fee schedule, but with important differences: it is negotiated between the National Association of Statutory Health Insurance Physicians and the national association of statutory sickness funds, and it operates within Germany’s corporatist, self-governing statutory insurance system rather than through unilateral CMS rulemaking.
Main Ideas for U.S. Readers
The German decision is best understood as a paired move: modernize the recognition of genomic medicine, but recapture the productivity gains of modern sequencing. The committee explicitly recognizes that clinical genetics has changed dramatically since the last major EBM update in 2016. More causal genes are known, sequencing technologies have advanced, and larger analyses are now routine. Germany is therefore redesigning EBM Chapter 11.4 for constitutional genetic testing — essentially germline or inherited genetic change — rather than treating current genomic practice as an awkward extension of older molecular genetics codes.
But this is not a pure expansion. The German payment system is using the same rulemaking package to lower valuations, introduce volume degressions, and prevent broad sequencing from becoming an open-ended spending category. This is the central policy lesson for U.S. diagnostics experts: Germany is treating genomics as clinically legitimate and operationally mature, but also as a scalable laboratory service whose average costs have fallen.
The most visible structural change is an indication-first architecture. Germany will organize many human genetic services around disease-group entry codes, numbered 11700 through 11708, with molecular and cytogenetic services billed as add-ons. That differs from the U.S. CPT and PLA environment, where the code often reflects an analyte, panel, platform, proprietary assay, or laboratory-developed test. Germany’s design begins with the clinical question: what disease group is being evaluated, and what scope of testing is medically necessary?
The second big move is the replacement of older cumulative sequence-length billing with fixed sequencing tiers. For certain rare-disease genetic testing, the new codes 11724 through 11727 establish flat-rate services tied to defined sequencing scope. This is a familiar policy problem in a new form: once sequencing becomes cheap and broad, payers no longer want billing systems that multiply payment mechanically with every additional increment of DNA.
The third major policy element is explicit reanalysis payment. Germany is adding code 11743 for renewed bioinformatic analysis of existing data from a prior large sequencing test when international evaluation standards have changed and the original question remains unanswered. This recognizes a practical reality in genetics: sometimes the right next step is not another sequencing run, but a fresh interpretation of existing data.
The fourth major element is volume management. Germany is adding practice-level degressions so that high-volume providers receive lower marginal reimbursement above specified quarterly thresholds. This is not unlike a nationalized version of the U.S. concern about high-throughput genetic testing, but the implementation is different. The U.S. typically relies on CPT coding, PLA codes, local coverage decisions, MolDx-type edits, prior authorization, and post-payment review. Germany is embedding the control mechanism directly in the national fee schedule.
Deeper Dive:Coding Architecture, Reanalysis, Prenatal Rules,Specialist Boundaries, and Volume Controls
The two PDFs tell different parts of the story. The 8-page explanatory memorandum provides the rationale: the legal basis, the history of the 2016 update, the scientific and technical changes in sequencing, and the committee’s reasoning for repricing and restructuring. The 35-page operative decision provides the actual EBM amendments: code language, exclusions, point values, billing restrictions, degression thresholds, and transitional provisions.
The German legal framework is important. The EBM is not merely a list of codes. It is the negotiated national valuation system for outpatient physician services in the statutory health insurance system. The parties are the Kassenärztliche Bundesvereinigung — the national association of statutory health insurance physicians — and the GKV-Spitzenverband, the national association of statutory sickness funds. The committee states that EBM service descriptions and valuations must reflect the current state of medical science and technology.
The committee’s core premise is that human genetics has outgrown the 2016 framework. It says the number of known disease-causing genes has multiplied, and that sequencing technology has opened new diagnostic possibilities. As a result, Section 11.4 EBM is comprehensively revised for human genetic in-vitro diagnostic services. The decision preserves and simplifies one subsection, restructures another, and folds the former Section 11.4.4 into the new Section 11.4.3.
The restructuring is carefully bounded. Section 11.4 remains focused on constitutional genetic changes in tissues and organs. The operative decision states that gene-expression analyses and analyses of free nucleic acids in plasma are not billable under this section. For a U.S. reader, that is a notable boundary: this package is not a German version of MolDx oncology CGP coverage, liquid biopsy coverage, or gene-expression classifier payment. It is a germline human genetics payment reform.
The new disease-group codes 11700 through 11708 are intended to improve transparency. If more than one disease group could apply, the most appropriate group should be selected based on the indication, preferably according to the leading clinical symptom or the pathology most likely expected at the time of ordering. The explanatory memorandum emphasizes that these disease groups are not intended to expand or restrict the historical scope of reimbursable human genetic services.
The committee also keeps a firm medical-necessity frame around testing. It states that human genetic testing generally should occur only when therapeutic options are available and when the diagnosis cannot already be made with sufficient certainty. The billed scope may not exceed what is necessary. This is a German analogue to the U.S. “reasonable and necessary” concept, but it is expressed directly in the fee-schedule logic rather than only in coverage-policy prose.
The technical services are built as add-ons to the indication codes. The molecular genetic and cytogenetic testing services in the new Section 11.4.3 are designed as surcharge positions to the disease-group codes. Codes 11700 through 11708 are generally billable once per “case of illness” — Krankheitsfall — and the committee cautions against repeating the same genetic scope and method merely because there is a new indication statement. In U.S. terms, Germany is trying to prevent a second clinical framing from triggering a second payment for the same underlying analytic work.
Sequencing tiering is one of the most consequential changes. The prior code 11513 for rare genetic disease diagnostics had allowed cumulative billing per 250 base pairs up to a maximum sequence length. The new framework replaces that with fixed payments under codes 11724 through 11727, each tied to a different sequencing scope. The committee states that this reflects technical and scientific progress and expands the analytic scope represented in the EBM.
The decision also distinguishes between raw sequencing and clinically relevant evaluated sequence. One operative provision states that the service content of codes 11724 through 11727 is determined by the scope of coding sequence length to be evaluated for the clinical question, not by the sequence length of raw data. That language is important. It shows that Germany is not paying for data volume as such. It is paying for the clinically indicated evaluated portion of the genome.
Reanalysis receives two separate forms of recognition. Code 11303 covers renewed assessment and reporting of variants of uncertain significance or likely pathogenic relevance, with the new rule allowing reassessment after one year so that scientific advances can be used in care more quickly. Separately, new code 11743 covers renewed bioinformatic analysis of existing data from a prior 11727 test when international standards have changed and the original question remains unresolved. In the latter case, the point is to avoid repeat sequencing when reinterpretation of already generated data is the needed service.
Complex interpretation is also separated from the sequencing itself. Existing physician assessment codes are revised, and new code 11305 is added for the physician assessment and reporting of complex genetic analyses above 40 kilobases. That service is restricted to specialists in human genetics or physicians with additional medical genetics qualification. The rule reflects a broader German pattern: payment is tied not only to the service but also to professional qualification and authorization.
The decision also creates or preserves several important exclusions and non-duplication rules. Hereditary breast and ovarian cancer testing, for example, is payable exclusively under code 11440. Pharmacogenetic testing related to drug metabolism or drug effect is not payable under the broader sequencing section. Several codes cannot be billed together in the same treatment case or illness case, reflecting an effort to avoid stacking of overlapping genetic services.
Prenatal testing is handled cautiously. Certain genetic services remain generally postnatal. However, selected services may be billed prenatally in exceptional cases when medically necessary. The operative decision requires that the genetic test be suitable to open therapeutic options or influence peripartum management, and that the medical necessity be justified in writing to the responsible regional physicians’ association. It also requires an abnormal ultrasound finding by a specially qualified examiner under the maternity guideline. Each fetus is treated as a separate illness case for these purposes, and special billing identification is required.
The economic rationale is unusually explicit. The explanatory memorandum states that valuations in Section 11.4 have largely remained unchanged since the 2016 introduction, while sequencing volumes have risen significantly. It also states that over the past decade the costs of analytic equipment relative to capacity and the costs of consumables have fallen significantly. Even with increased personnel costs, the committee concludes that average costs per test have fallen, especially for large laboratories because of scale effects.
That premise leads directly to price and volume controls. The package lowers valuations for many human genetic services and introduces additional degression for high-revenue practices. Most Section 11.4 services, excluding Section 11.4.1 and cytogenetic services 11715 through 11719, are subject to a 20 percent reduction once a practice exceeds 841,769 points in a quarter for the relevant services. The definition of “practice” is broad and aggregates main and branch operating sites, including solo practices, group practices, employed-physician practices, medical care centers, authorized physicians, and authorized institutions.
A separate degression applies to codes 11723 through 11728, 11730 through 11732, and 11743. Once a practice exceeds 3,964,594 points per quarter for those services, payments above the threshold are reduced by 25 percent. Code 11440, the hereditary breast and ovarian cancer code, receives a separate practice-level degression: above 1,092,939 quarterly points, payment above the threshold is reduced by 25 percent. Physician assessment codes 11302 and 11305 also receive a practice-level 20 percent degression above 1,413,278 quarterly points.
The package is therefore not only a recoding initiative, but a targeted response to laboratory concentration and high-throughput economics. The German committee is saying, in effect, that large-volume genetic testing practices have lower marginal costs and should not receive the same marginal payment indefinitely.
There is also a budgetary transition. A companion recommendation provides for a one-time, non-base-building payment from sickness funds equal to 20 percent of any 2026 volume growth over 2025 for the affected services. That is a subtle but important mechanism. Germany acknowledges short-term growth in service use while preventing that growth from automatically becoming part of the permanent payment base.
For the U.S. audience, the comparison is instructive. In Medicare, genomic payment disputes usually appear as CPT valuation debates, PLA code pricing, gapfill decisions, MolDx coverage articles, local coverage determinations, prior-authorization policies, or payer edits. Germany’s new EBM package uses a different tool: a national negotiated fee schedule that can simultaneously modernize the coding architecture, define clinical boundaries, lower valuations, and impose marginal volume discounts.
The result is a sophisticated but austere genomic payment reform. Germany is not denying the importance of next-generation sequencing. On the contrary, it is building broader sequencing, reanalysis, variant reinterpretation, and indication-based ordering into the national payment system. But it is doing so on the assumption that modern sequencing is now a scalable service with declining unit costs — and that public insurance should capture some of those efficiencies.
For U.S. policy experts, that is the main lesson. Recognition of genomic medicine does not necessarily mean higher payment. In Germany’s 2026 EBM reform, recognition and restraint arrive together.
Source anchors: the 8-page explanatory memorandum says the EBM update is grounded in §87 SGB V, revises Chapter 11.4 effective Oct. 1, 2026, and responds to major advances in gene discovery and sequencing technology since the last major 2016 update. It describes the structural changes to codes 11301, 11303, 11305, 11440, 11700–11708, and the consolidation of 11.4.3/11.4.4. The 35-page operative decision contains the actual EBM rule text, including exclusions for gene-expression and plasma free-nucleic-acid analyses, prenatal documentation requirements, rare-disease limitations, and volume degression thresholds. The 8-page explanatory memorandum also states the economic rationale: sequencing volumes have grown, equipment and consumables costs have fallen relative to capacity, and the committee is lowering valuations and adding degression to constrain spending growth.
